Association of serum CC16 levels with eosinophilic inflammation and respiratory dysfunction in severe asthma
Copyright © 2022 Elsevier Ltd. All rights reserved..
BACKGROUND: There are knowledge gaps in the potential role of Club cell 16-kDa secretory protein (CC16) in severe asthma phenotypes and type 2 inflammation, as well as the longitudinal effect of CC16 on pulmonary function tests and exacerbation risk in epidemiological studies.
OBJECTIVE AND METHODS: To assess whether serum CC16 is associated with eosinophilic inflammation in patients with severe asthma. We also examined the effect of this protein on the annual decline in forced expiratory volume in the first second (FEV1) and the risk of exacerbation using a longitudinal approach. We recruited 127 patients with severe asthma from 30 hospitals/pulmonary clinics in Hokkaido, Japan. The least square means and standard error were calculated for T-helper 2 (Th2) biomarkers and pulmonary function test across CC16 tertiles at baseline. We did the same for asthma exacerbation and annual decline in FEV1 with 3 and 5 years' follow-up, respectively.
RESULTS: We found that serum CC16 was inversely associated with sputum eosinophils and blood periostin in a dose-response manner. Baseline CC16 and FEV1/forced vital capacity ratio were positively associated in adjusted models (p for trend = 0.008). Patients with the lowest tertile of serum CC16 levels at baseline had a -14.3 mL decline in FEV1 than those with the highest tertile over 5 years of follow-up (p for trend = 0.031, fully adjusted model). We did not find any association of CC16 with exacerbation risk.
CONCLUSION: Patients with severe asthma with lower circulatory CC16 had enhanced eosinophilic inflammation with rapid FEV1 decline over time.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:206 |
|---|---|
| Enthalten in: |
Respiratory medicine - 206(2023) vom: 15. Jan., Seite 107089 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goudarzi, Houman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CC16 |
|---|
| Anmerkungen: |
Date Completed 03.01.2023 Date Revised 03.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmed.2022.107089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350545448 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350545448 | ||
| 003 | DE-627 | ||
| 005 | 20231226045236.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rmed.2022.107089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350545448 | ||
| 035 | |a (NLM)36542961 | ||
| 035 | |a (PII)S0954-6111(22)00354-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goudarzi, Houman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of serum CC16 levels with eosinophilic inflammation and respiratory dysfunction in severe asthma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.01.2023 | ||
| 500 | |a Date Revised 03.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: There are knowledge gaps in the potential role of Club cell 16-kDa secretory protein (CC16) in severe asthma phenotypes and type 2 inflammation, as well as the longitudinal effect of CC16 on pulmonary function tests and exacerbation risk in epidemiological studies | ||
| 520 | |a OBJECTIVE AND METHODS: To assess whether serum CC16 is associated with eosinophilic inflammation in patients with severe asthma. We also examined the effect of this protein on the annual decline in forced expiratory volume in the first second (FEV1) and the risk of exacerbation using a longitudinal approach. We recruited 127 patients with severe asthma from 30 hospitals/pulmonary clinics in Hokkaido, Japan. The least square means and standard error were calculated for T-helper 2 (Th2) biomarkers and pulmonary function test across CC16 tertiles at baseline. We did the same for asthma exacerbation and annual decline in FEV1 with 3 and 5 years' follow-up, respectively | ||
| 520 | |a RESULTS: We found that serum CC16 was inversely associated with sputum eosinophils and blood periostin in a dose-response manner. Baseline CC16 and FEV1/forced vital capacity ratio were positively associated in adjusted models (p for trend = 0.008). Patients with the lowest tertile of serum CC16 levels at baseline had a -14.3 mL decline in FEV1 than those with the highest tertile over 5 years of follow-up (p for trend = 0.031, fully adjusted model). We did not find any association of CC16 with exacerbation risk | ||
| 520 | |a CONCLUSION: Patients with severe asthma with lower circulatory CC16 had enhanced eosinophilic inflammation with rapid FEV1 decline over time | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CC16 | |
| 650 | 4 | |a Eosinophilic inflammation | |
| 650 | 4 | |a Periostin | |
| 650 | 4 | |a Respiratory function | |
| 650 | 4 | |a Severe asthma | |
| 650 | 4 | |a Sputum eosinophils | |
| 650 | 4 | |a T-helper 2 biomarkers | |
| 700 | 1 | |a Kimura, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Kimura, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Makita, Hironi |e verfasserin |4 aut | |
| 700 | 1 | |a Takimoto-Sato, Michiko |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Oguma, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Munehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takei, Nozomu |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto-Sasaki, Machiko |e verfasserin |4 aut | |
| 700 | 1 | |a Shimizu, Kaoruko |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Shijubo, Noriharu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shau-Ku |e verfasserin |4 aut | |
| 700 | 1 | |a Hizawa, Nobuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Konno, Satoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory medicine |d 1993 |g 206(2023) vom: 15. Jan., Seite 107089 |w (DE-627)NLM012605247 |x 1532-3064 |7 nnns |
| 773 | 1 | 8 | |g volume:206 |g year:2023 |g day:15 |g month:01 |g pages:107089 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmed.2022.107089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 206 |j 2023 |b 15 |c 01 |h 107089 | ||